Claims for Patent: 6,713,293

Summary for Patent: 6,713,293

Title:	Encapsulated cells containing an amplified expression vector as a drug delivery device
Abstract:	The present invention provides a drug delivery device comprising encapsulated cells that contain multiple copies of an expression cassette. The drug delivery device of the present invention is useful to supply an animal, including a human, with a therapeutically desirable molecule, including physiological activities lacking in disease conditions or antagonist against conditions in an animal, especially a human.
Inventor(s):	Grummt; Friedrich (Wurzburg, DE), Sauer; Birgitta (Penzberg, DE), Muller; Martha (Wurzburg, DE)
Assignee:
Application Number:	09/246,309
Patent Claims:	1. An encapsulated population of cells comprising (a) a eukaryotic cell; (b) an exogenous polynucleotide comprising an expression cassette and an amplification-promoting sequence, said eukaryotic cell comprising said polynucleotide, wherein said expression cassette is stably expressed and comprises a nucleic acid encoding an insulin, an insulin precursor polypeptide, a serotonin, a neurotropic factor, a neurotrophic factor, a tyrosine hydroxylase, a tryptophan hydroxylase, an enkephalin, an enkephalin precursor polypeptide, an enkephalinase, a melanoma inhibitory activity and parathyroid hormone and wherein said amplification-promoting sequence comprises a polynucleotide that is capable of hybridizing under highly stringent conditions to a polynucleotide that is complementary to SEQ ID NO:1 or SEQ ID NO:2; and (c) a capsule, said eukaryotic cell being located in the interior of said capsule. 2. The encapsulated population of cells of claim 1, wherein the amplification-promoting sequence is a polynucleotide comprising the sequence of SEQ ID NO:1. 3. The encapsulated population of cells of claim 1, wherein the amplification-promoting sequence is a polynucleotide comprising the sequence of SEQ ID NO:2. 4. The encapsulated population of cells of claim 1, wherein the amplification-promoting sequence comprises a polynucleotide that is capable of hybridizing under highly stringent conditions to a polynucleotide that is complementary to SEQ ID NO:1. 5. The encapsulated population of cells of claim 1, wherein the amplification-promoting sequence comprises a polynucleotide that is capable of hybridizing under highly stringent conditions to a polynucleotide that is complementary to SEQ ID NO:2. 6. The encapsulated population of cells of claim 1, wherein the expression cassette comprises a coding polynucleotide sequence and a regulatory polynucleotide sequence. 7. The encapsulated population of cells of claim 6, wherein the regulatory polynucleotide sequence comprises a promoter and a polyA signal. 8. The encapsulated population of cells of claim 7, wherein the regulatory polynucleotide sequence further comprises a regulatory polynucleotide sequence selected from the group consisting of an intron, an enhancer, a 5' untranslated region, a 3' untranslated region and an RNA stability regulating sequence. 9. The encapsulated population of cells of claim 7, wherein the promoter is inducible. 10. The encapsulated population of cells of claim 7, wherein the promoter is constitutive. 11. The encapsulated population of cells of claim 1, wherein the exogenous polynucleotide further comprises a selectable marker. 12. The encapsulated population of cells of claim 11, wherein the selectable marker confers the ability to grow under selective growth conditions. 13. The encapsulated population of cells of claim 12, wherein the selectable marker is selected from the group consisting of the neomycin resistance gene and the hypoxanthine phosphoribosyltransferase gene. 14. The encapsulated population of cells of claim 1, wherein the capsule is double layered. 15. The encapsulated population of cells of claim 1, wherein the capsule comprises an inner core and an outer shell. 16. The encapsulated population of cells of claim 15, wherein the eukaryotic cell is located in the inner core. 17. The encapsulated population of cells of claim 15, wherein the capsule was made using alginate. 18. The encapsulated population of cells of claim 17, wherein substantially all of from about 40 to about 1000 eukaryotic cells, into which said exogenous polynucleotide has been introduced, are located in the inner core. 19. The encapsulated population of cells of claim 17, wherein substantially all of from about 60 to about 500 eukaryotic cells, into which said exogenous polynucleotide has been introduced, are located in the inner core. 20. The encapsulated population of cells of claim 17, wherein substantially all of from about 80 to about 250 eukaryotic cells, into which said exogenous polynucleotide has been introduced, are located in the inner core. 21. The encapsulated population of cells of claim 17, wherein substantially all of from about 80 to about 120 eukaryotic cells, into which said exogenous polynucleotide has been introduced, are located in the inner core.

Details for Patent 6,713,293

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26